Desloratadyna – lek skuteczny, lek bezpieczny Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
cze 30, 2015
Słowa kluczowe:
alergiczny nieżyt nosa, pokrzywka, desloratadyna
##plugins.themes.bootstrap3.article.main##
Abstrakt
Leczeniem z wyboru znacznej części alergicznych nieżytów nosa, a także pokrzywek przewlekłych jest stosowanie doustnie leku przeciwhistaminowego. Na rynku mamy szereg rozmaitych leków należących do tej grupy. Jednym z nich jest desloratadyna. Lek ten charakteryzuje się wysoką skutecznością i bezpieczeństwem, niezależnie od wieku pacjentów. Niniejsza praca przybliża dane farmakologiczne i kliniczne dotyczące tego preparatu.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Pawliczak , R. (2015). Desloratadyna – lek skuteczny, lek bezpieczny . Medycyna Faktów , 8(2(27), 68-73. Pobrano z https://journalsmededu.pl/index.php/jebm/article/view/2314
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Papi A., Papadopoulos N.G., Stanciu L.A. et al.: Effect of desloratadine and loratadine on rhinovirus-induced intercellular adhesion molecule 1 upregulation and promoter activation in respiratory epithelial cells. J. Allergy Clin. Immunol. 2001; 108(2): 221-228.
2. Ciebiada M., Barylski M., Gorska Ciebiada M.: Nasal eosinophilia and serum soluble intercellular adhesion molecule 1 in patients with allergic rhinitis treated with montelukast alone or in combination with desloratadine or levocetirizine. Am. J. Rhinol. Allergy 2013; 27(2): e58-e62.
3. Agrawal D.K.: Pharmacology and clinical efficacy of desloratadine as an anti-allergic and anti-inflammatory drug. Expert Opin. Investig Drugs 2001; 10(3): 547-560.
4. Bachert C.: Decongestant efficacy of desloratadine in patients with seasonal allergic rhinitis. Allergy 2001; 56(supl. 65): 14-20.
5. Baena-Cagnani C.E.: Desloratadine activity in concurrent seasonal allergic rhinitis and asthma. Allergy 2001; 56(supl. 65): 21-27.
6. Barecki M.E. Casciano C.N., Johnson W.W. et al.: In vitro characterization of the inhibition profile of loratadine, desloratadine, and 3-OH-desloratadine for five human cytochrome P-450 enzymes. Drug. Metab. Dispos. 2001; 29(9): 1173-1175.
7. Bonini S.: Desloratadine: a new approach in the treatment of allergy as a systematic disease-pharmacology and clinical overview. Introduction. Allergy 2001; 56(supl. 65): 5-6.
8. Geha R.S., Meltzer E.O.: Desloratadine: A new, nonsedating, oral antihistamine. J. Allergy Clin. Immunol. 2001; 107(4): 751-762.
9. Gupta S., Banfield C., Kantesaria B. et al.: Pharmacokinetic and safety profile of desloratadine and fexofenadine when coadministered with azithromycin: a randomized, placebo-controlled, parallel-group study. Clin. Ther. 2001; 23(3): 451-466.
10. Henz B.M.: The pharmacologic profile of desloratadine: a review. Allergy 2001; 56(supl. 65): 7-13.
11. Canonica G.W., Blaiss M.: Antihistaminic, anti-inflammatory, and antiallergic properties of the nonsedating second-generation antihistamine desloratadine: a review of the evidence. World Allergy Organ J. 2011; 4(2): 47-53.
12. Bachert C., Maurer M.: Safety and efficacy of desloratadine in subjects with seasonal allergic rhinitis or chronic urticaria: results of four postmarketing surveillance studies. Clin. Drug Investig. 2010; 30(2): 109-122.
13. Bousquet J., Bachert C., Canonica G.W. et al.: Efficacy of desloratadine in persistent allergic rhinitis – a GA(2)LEN study. Int. Arch. Allergy Immunol. 2010; 153(4): 395-402.
14. Bousquet J., Zuberbier T., Canonica G.W. et al.: Randomized controlled trial of desloratadine for persistent allergic rhinitis: correlations between symptom improvement and quality of life. Allergy Asthma Proc. 2012; 34(3): 274-282.
15. Lukat K., Rivas P., Roger A. et al.: A direct comparison of efficacy between desloratadine and rupatadine in seasonal allergic rhinoconjunctivitis: a randomized, double-blind, placebo-controlled study. J. Asthma Allergy 2013; 6: 31-39.
16. Affrime M., Gupta S., Banfield C. et al.: A pharmacokinetic profile of desloratadine in healthy adults, including elderly. Clin. Pharmacokinet. 2002; 41(supl. 1): 13-19.
17. Gupta S., Khalilieh S., Kantesaria B. et al.: Pharmacokinetics of desloratadine in children between 2 and 11 years of age. Br. J. Clin. Pharmacol. 2007; 63(5): 534-540.
18. Gonzalez-Nunez V., Valero A., Mullol J.: Safety evaluation of desloratadine in allergic rhinitis. Expert Opin. Drug Saf. 2013; 12(3): 445-453.
19. Layton D., Wilton L., Boshier A. et al.: Comparison of the risk of drowsiness and sedation between levocetirizine and desloratadine: a prescription- event monitoring study in England. Drug Saf. 2006; 29(10): 897-909.
20. Vuurman E.F., Rikken G.H., Muntjewerff N.D. et al.: Effects of desloratadine, diphenhydramine, and placebo on driving performance and psychomotor performance measurements. Eur. J. Clin. Pharmacol. 2004; 60(5): 307-313.
21. Hong J.B., Lee H.C., Hu F.C. et al.: A randomized, double-blind, active-controlled, parallel-group pilot study to compare the efficacy and sedative effects of desloratadine 5 mg with levocetirizine 5 mg in the treatment of chronic idiopathic urticaria. J. Am. Acad. Dermatol. 2010; 63(5): e100-e102.
22. Kazmi F., Barbara J.E., Yerino P. et al.: A long-standing mystery solved: the formation of 3-hydroxydesloratadine is catalyzed by CYP2C8 but prior glucuronidation of desloratadine by UDP-glucuronosyltransferase 2B10 is an obligatory requirement. Drug Metab. Dispos. 2015; 43(4): 523-533.
23. Wang E.J., Casciano C.N., Clement R.P. et al.: Evaluation of the interaction of loratadine and desloratadine with P-glycoprotein. Drug Metab. Dispos 2001; 29(8): 1080-1083.
24. Staevska M., Popov T.A., Kralimarkova T. et al.: The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria. J. Allergy Clin. Immunol. 2010; 125(3): 676-682.
25. Augustin M., Ehrle S.: Safety and efficacy of desloratadine in chronic idiopathic urticaria in clinical practice: an observational study of 9246 patients. J. Eur. Acad. Dermatol. Venereol. 2009; 23(3): 292-299.
26. Siebenhaar F., Degener F., Zuberbier T. et al.: High-dose desloratadine decreases wheal volume and improves cold provocation thresholds compared with standard-dose treatment in patients with acquired cold urticaria: a randomized, placebo-controlled, crossover study. J. Allergy Clin. Immunol. 2009; 123(3): 672-679.
27. Villa E., Rogkakou A., Garelli V. et al.: Review of Desloratadine Data Using the ARIA Guidelines. World Allergy Organ J. 2012; 5(supl. 1): S6-S13.
2. Ciebiada M., Barylski M., Gorska Ciebiada M.: Nasal eosinophilia and serum soluble intercellular adhesion molecule 1 in patients with allergic rhinitis treated with montelukast alone or in combination with desloratadine or levocetirizine. Am. J. Rhinol. Allergy 2013; 27(2): e58-e62.
3. Agrawal D.K.: Pharmacology and clinical efficacy of desloratadine as an anti-allergic and anti-inflammatory drug. Expert Opin. Investig Drugs 2001; 10(3): 547-560.
4. Bachert C.: Decongestant efficacy of desloratadine in patients with seasonal allergic rhinitis. Allergy 2001; 56(supl. 65): 14-20.
5. Baena-Cagnani C.E.: Desloratadine activity in concurrent seasonal allergic rhinitis and asthma. Allergy 2001; 56(supl. 65): 21-27.
6. Barecki M.E. Casciano C.N., Johnson W.W. et al.: In vitro characterization of the inhibition profile of loratadine, desloratadine, and 3-OH-desloratadine for five human cytochrome P-450 enzymes. Drug. Metab. Dispos. 2001; 29(9): 1173-1175.
7. Bonini S.: Desloratadine: a new approach in the treatment of allergy as a systematic disease-pharmacology and clinical overview. Introduction. Allergy 2001; 56(supl. 65): 5-6.
8. Geha R.S., Meltzer E.O.: Desloratadine: A new, nonsedating, oral antihistamine. J. Allergy Clin. Immunol. 2001; 107(4): 751-762.
9. Gupta S., Banfield C., Kantesaria B. et al.: Pharmacokinetic and safety profile of desloratadine and fexofenadine when coadministered with azithromycin: a randomized, placebo-controlled, parallel-group study. Clin. Ther. 2001; 23(3): 451-466.
10. Henz B.M.: The pharmacologic profile of desloratadine: a review. Allergy 2001; 56(supl. 65): 7-13.
11. Canonica G.W., Blaiss M.: Antihistaminic, anti-inflammatory, and antiallergic properties of the nonsedating second-generation antihistamine desloratadine: a review of the evidence. World Allergy Organ J. 2011; 4(2): 47-53.
12. Bachert C., Maurer M.: Safety and efficacy of desloratadine in subjects with seasonal allergic rhinitis or chronic urticaria: results of four postmarketing surveillance studies. Clin. Drug Investig. 2010; 30(2): 109-122.
13. Bousquet J., Bachert C., Canonica G.W. et al.: Efficacy of desloratadine in persistent allergic rhinitis – a GA(2)LEN study. Int. Arch. Allergy Immunol. 2010; 153(4): 395-402.
14. Bousquet J., Zuberbier T., Canonica G.W. et al.: Randomized controlled trial of desloratadine for persistent allergic rhinitis: correlations between symptom improvement and quality of life. Allergy Asthma Proc. 2012; 34(3): 274-282.
15. Lukat K., Rivas P., Roger A. et al.: A direct comparison of efficacy between desloratadine and rupatadine in seasonal allergic rhinoconjunctivitis: a randomized, double-blind, placebo-controlled study. J. Asthma Allergy 2013; 6: 31-39.
16. Affrime M., Gupta S., Banfield C. et al.: A pharmacokinetic profile of desloratadine in healthy adults, including elderly. Clin. Pharmacokinet. 2002; 41(supl. 1): 13-19.
17. Gupta S., Khalilieh S., Kantesaria B. et al.: Pharmacokinetics of desloratadine in children between 2 and 11 years of age. Br. J. Clin. Pharmacol. 2007; 63(5): 534-540.
18. Gonzalez-Nunez V., Valero A., Mullol J.: Safety evaluation of desloratadine in allergic rhinitis. Expert Opin. Drug Saf. 2013; 12(3): 445-453.
19. Layton D., Wilton L., Boshier A. et al.: Comparison of the risk of drowsiness and sedation between levocetirizine and desloratadine: a prescription- event monitoring study in England. Drug Saf. 2006; 29(10): 897-909.
20. Vuurman E.F., Rikken G.H., Muntjewerff N.D. et al.: Effects of desloratadine, diphenhydramine, and placebo on driving performance and psychomotor performance measurements. Eur. J. Clin. Pharmacol. 2004; 60(5): 307-313.
21. Hong J.B., Lee H.C., Hu F.C. et al.: A randomized, double-blind, active-controlled, parallel-group pilot study to compare the efficacy and sedative effects of desloratadine 5 mg with levocetirizine 5 mg in the treatment of chronic idiopathic urticaria. J. Am. Acad. Dermatol. 2010; 63(5): e100-e102.
22. Kazmi F., Barbara J.E., Yerino P. et al.: A long-standing mystery solved: the formation of 3-hydroxydesloratadine is catalyzed by CYP2C8 but prior glucuronidation of desloratadine by UDP-glucuronosyltransferase 2B10 is an obligatory requirement. Drug Metab. Dispos. 2015; 43(4): 523-533.
23. Wang E.J., Casciano C.N., Clement R.P. et al.: Evaluation of the interaction of loratadine and desloratadine with P-glycoprotein. Drug Metab. Dispos 2001; 29(8): 1080-1083.
24. Staevska M., Popov T.A., Kralimarkova T. et al.: The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria. J. Allergy Clin. Immunol. 2010; 125(3): 676-682.
25. Augustin M., Ehrle S.: Safety and efficacy of desloratadine in chronic idiopathic urticaria in clinical practice: an observational study of 9246 patients. J. Eur. Acad. Dermatol. Venereol. 2009; 23(3): 292-299.
26. Siebenhaar F., Degener F., Zuberbier T. et al.: High-dose desloratadine decreases wheal volume and improves cold provocation thresholds compared with standard-dose treatment in patients with acquired cold urticaria: a randomized, placebo-controlled, crossover study. J. Allergy Clin. Immunol. 2009; 123(3): 672-679.
27. Villa E., Rogkakou A., Garelli V. et al.: Review of Desloratadine Data Using the ARIA Guidelines. World Allergy Organ J. 2012; 5(supl. 1): S6-S13.